You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2005: the combination of opioids, cocaine, cannabis or other stimulants as primary drug type with a secondary drug [see all tables in this series...]

Part (i) Most frequent combination of the primary drug with the stated types of secondary drug (percentages)

Primary drug	Primary drug	Secondary drug
Primary drug	Number of clients	Opioids	Cocaine	Other stimulants	Hypnotics/sedatives	Hallucinogens	Volatile substances	Cannabis	Alcohol	Other substances
Opioids	115273	34.5	23.3	4.2	8.0	1.0	0.1	16.9	10.7	1.3
Cocaine	24319	16.1	16.6	9.8	2.6	1.7	0.2	27.7	23.1	2.1
Cannabis	26343	6.8	15.4	27.9	3.8	5.4	1.0	0.1	36.8	2.8
Stimulants	13144	5.4	10.5	34.1	2.9	4.6	0.6	26.3	13.0	2.5

Notes:

Countries included: BG, CZ, DK, DE, IE, EL, FR, IT, CY, LU, MT, NL, SK, FI, SE, UK.

Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients.

'Opioids' include: heroin, methadone, other opioids; 'Cocaine' includes: cocaine HCl, crack cocaine; 'Stimulants' include: amphetamines, MDMA and derivates, other stimulants: 'Cannabis' can include herb or resin. For each client up to four secondary drugs can be reported.

A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI protocol for the drugs categories. The greater part of clients using cannabis both as primary and secondary drug comes from Germany.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

2006 Reitox national reports.